-
1
-
-
0034669656
-
Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology Group trials
-
Manola J, Atkins M, Ibrahim J, et al: Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18:3782-3793, 2000
-
(2000)
J Clin Oncol
, vol.18
, pp. 3782-3793
-
-
Manola, J.1
Atkins, M.2
Ibrahim, J.3
-
2
-
-
0035880957
-
Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
-
Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
-
(2001)
J Clin Oncol
, vol.19
, pp. 3622-3634
-
-
Balch, C.M.1
Soong, S.J.2
Gershenwald, J.E.3
-
3
-
-
0030030347
-
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
-
Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17, 1996
-
(1996)
J Clin Oncol
, vol.14
, pp. 7-17
-
-
Kirkwood, J.M.1
Strawderman, M.H.2
Ernstoff, M.S.3
-
4
-
-
0034088027
-
High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
-
Kirkwood JM, Ibrahim JG, Sondak VK, et al: High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18:2444-2458, 2000
-
(2000)
J Clin Oncol
, vol.18
, pp. 2444-2458
-
-
Kirkwood, J.M.1
Ibrahim, J.G.2
Sondak, V.K.3
-
5
-
-
0035339880
-
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801
-
Kirkwood JM, Ibrahim JG, Sosman JA, et al: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380, 2001
-
(2001)
J Clin Oncol
, vol.19
, pp. 2370-2380
-
-
Kirkwood, J.M.1
Ibrahim, J.G.2
Sosman, J.A.3
-
6
-
-
1842533233
-
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma: Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy
-
Kirkwood JM, Manola J, Ibrahim J, et al: A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma: Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. Clin Cancer Res 10:1670-1677, 2004
-
(2004)
Clin Cancer Res
, vol.10
, pp. 1670-1677
-
-
Kirkwood, J.M.1
Manola, J.2
Ibrahim, J.3
-
7
-
-
46749103710
-
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial
-
Eggermont AM, Suciu S, Santinami M, et al: Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial. Lancet 372:117-126, 2008
-
(2008)
Lancet
, vol.372
, pp. 117-126
-
-
Eggermont, A.M.1
Suciu, S.2
Santinami, M.3
-
8
-
-
0029739081
-
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study
-
Cole BF, Gelber RD, Kirkwood JM, et al: Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 14:2666-2673, 1996
-
(1996)
J Clin Oncol
, vol.14
, pp. 2666-2673
-
-
Cole, B.F.1
Gelber, R.D.2
Kirkwood, J.M.3
-
9
-
-
0035253368
-
Patient preferences for adjuvant interferon alfa-2b treatment
-
Kilbridge KL, Weeks JC, Sober AJ, et al: Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol 19:812-823, 2001
-
(2001)
J Clin Oncol
, vol.19
, pp. 812-823
-
-
Kilbridge, K.L.1
Weeks, J.C.2
Sober, A.J.3
-
10
-
-
0036499079
-
Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data
-
Kilbridge KL, Cole BF, Kirkwood JM, et al: Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol 20:1311-1318, 2002
-
(2002)
J Clin Oncol
, vol.20
, pp. 1311-1318
-
-
Kilbridge, K.L.1
Cole, B.F.2
Kirkwood, J.M.3
-
11
-
-
0036727090
-
Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy
-
Kirkwood JM, Bender C, Agarwala S, et al: Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 20:3703-3718, 2002
-
(2002)
J Clin Oncol
, vol.20
, pp. 3703-3718
-
-
Kirkwood, J.M.1
Bender, C.2
Agarwala, S.3
-
12
-
-
67649933805
-
Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: A phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group
-
Bottomley A, Coens C, Suciu S, et al: Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: A phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 27:2916-2923, 2009
-
(2009)
J Clin Oncol
, vol.27
, pp. 2916-2923
-
-
Bottomley, A.1
Coens, C.2
Suciu, S.3
-
13
-
-
46949091404
-
Adjuvant therapy of melanoma: Is pegylated interferon alfa-2b what we've been waiting for?
-
Sondak VK, Flaherty LE: Adjuvant therapy of melanoma: Is pegylated interferon alfa-2b what we've been waiting for? Lancet 372:89-90, 2008
-
(2008)
Lancet
, vol.372
, pp. 89-90
-
-
Sondak, V.K.1
Flaherty, L.E.2
-
14
-
-
32644454916
-
Prognostic significance of autoimmunity during treatment of melanoma with interferon
-
Gogas H, Ioannovich J, Dafni U, et al: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709-718, 2006
-
(2006)
N Engl J Med
, vol.354
, pp. 709-718
-
-
Gogas, H.1
Ioannovich, J.2
Dafni, U.3
|